Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Treasury Shares (2021 - 2026)

MoonLake Immunotherapeutics' Treasury Shares history spans 1 years, with the latest figure at $6202.0 for Q4 2021.

  • Quarterly Treasury Shares changed N/A to $6202.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $6202.0 through Dec 2021, changed N/A year-over-year, with the annual reading at $6202.0 for FY2021, N/A changed from the prior year.
  • Treasury Shares came in at $6202.0 for Q4 2021.
  • In the past five years, Treasury Shares ranged from a high of $2.8 million in Q2 2022 to a low of $191526.0 in Q2 2025.
  • The 5-year median for Treasury Shares is $1.4 million (2022), against an average of $1.3 million.
  • Year-over-year, Treasury Shares skyrocketed 192.35% in 2023 and then crashed 91.38% in 2025.
  • MoonLake Immunotherapeutics' Treasury Shares stood at $1.9 million in 2022, then crashed by 67.54% to $630490.0 in 2023, then skyrocketed by 252.28% to $2.2 million in 2024, then plummeted by 91.38% to $191526.0 in 2025, then skyrocketed by 159.99% to $497942.0 in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Treasury Shares are $497942.0 (Q1 2026), $191526.0 (Q4 2025), and $191526.0 (Q3 2025).